Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.

Autor: Pecci F; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Nakazawa S; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Harada G; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Lee JK; Foundation Medicine, Cambridge, Massachusetts., Alessi JV; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Barrichello A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Vaz VR; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lamberti G; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Di Federico A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gandhi MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gazgalis D; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Feng WW; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Jiang J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Baldacci S; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Locquet MA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gottlieb FH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chen MF; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Lee E; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Haradon D; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Smokovich A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Voligny E; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Nguyen T; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Goel VK; Turning Point Therapeutics, Bristol Myers Squibb Company, San Diego, California., Zimmerman Z; Turning Point Therapeutics, Bristol Myers Squibb Company, San Diego, California., Atwal S; Turning Point Therapeutics, Bristol Myers Squibb Company, San Diego, California., Wang X; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts., Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Heist RS; Massachusetts General Hospital, Boston, Massachusetts., Iqbal S; The Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts., Gandhi N; Caris Life Sciences, Phoenix, Arizona., Elliott A; Caris Life Sciences, Phoenix, Arizona., Vanderwalde AM; Caris Life Sciences, Phoenix, Arizona., Ma PC; Penn State Cancer Institute, Penn State College of Medicine, Penn State University, Hershey, Pennsylvania., Halmos B; Montefiore Einstein Cancer Center, Bronx, New York., Liu SV; Georgetown University, Washington, DC., Che J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schrock AB; Foundation Medicine, Cambridge, Massachusetts., Drilon A; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Aug 02; Vol. 14 (8), pp. 1440-1456.